Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Retained Earnings: 2021-2024

Historic Retained Earnings for Kiniksa Pharmaceuticals International (KNSA) over the last 4 years, with Dec 2024 value amounting to -$521.1 million.

  • Kiniksa Pharmaceuticals International's Retained Earnings rose 7.01% to -$476.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$476.3 million, marking a year-over-year increase of 7.01%. This contributed to the annual value of -$521.1 million for FY2024, which is 9.04% down from last year.
  • According to the latest figures from FY2024, Kiniksa Pharmaceuticals International's Retained Earnings is -$521.1 million, which was down 9.04% from -$477.9 million recorded in FY2023.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Retained Earnings registered a high of -$477.9 million during FY2023, and its lowest value of -$675.4 million during FY2021.
  • In the last 3 years, Kiniksa Pharmaceuticals International's Retained Earnings had a median value of -$492.0 million in 2022 and averaged -$497.0 million.
  • In the last 5 years, Kiniksa Pharmaceuticals International's Retained Earnings climbed by 27.15% in 2022 and then dropped by 9.04% in 2024.
  • Over the past 4 years, Kiniksa Pharmaceuticals International's Retained Earnings (Yearly) stood at -$675.4 million in 2021, then grew by 27.15% to -$492.0 million in 2022, then rose by 2.86% to -$477.9 million in 2023, then decreased by 9.04% to -$521.1 million in 2024.